

# PMR Public Report

|   |   |   |                                     |                        |                     |                        |                      |             |                    |
|---|---|---|-------------------------------------|------------------------|---------------------|------------------------|----------------------|-------------|--------------------|
| Operation Number  | EC-U0003  | Chief of Operations Validation Date                       | 03/31/22                            |                        |                     |                        |                      |             |                    |
| Year- PMR Cycle   | Second period Jan-Dec 2021                                    | Division Chief Validation Date                            | 04/11/22                            |                        |                     |                        |                      |             |                    |
| Last Update   | 03/25/22  | Country Representative Validation Date                    | 04/28/22                            |                        |                     |                        |                      |             |                    |
| PMR Validation Stage                                    | Validated by Representative                                   |   |                                     |                        |                     |                        |                      |             |                    |
| Basic Data  |   |   |                                     |                        |                     |                        |                      |             |                    |
| Operation Profile                                       |   |   |                                     |                        |                     |                        |                      |             |                    |
| Operation Name  | Support to the financing of the purchase of COVID-19 vaccines | Loan Number   | 5235/OC-EC                          |                        |                     |                        |                      |             |                    |
| Executing Agency  | MINISTERIO DE SALUD PUBLICA                                   | Sector/Subsector  | HEALTH-DISEASE PREVENTION & CONTROL |                        |                     |                        |                      |             |                    |
| Team Leader   | SAN ROMAN VUCETICH, CRISTINA                                  | Overall Stage   | Approved/Pending Signature          |                        |                     |                        |                      |             |                    |
| Operation Type  | Guarantee   | Country   | Ecuador                             |                        |                     |                        |                      |             |                    |
| Lending Instrument                                      | Investment  | Convergence related Operation(s)                          |                                     |                        |                     |                        |                      |             |                    |
| Borrower  | REPUBLICA DE ECUADOR  |   |                                     |                        |                     |                        |                      |             |                    |
| Environmental and Social Safeguards                     |   |   |                                     |                        |                     |                        |                      |             |                    |
| Impacts Category  | C   | Was/Were the objective(s) of this operation reformulated? | NO                                  |                        |                     |                        |                      |             |                    |
| Safeguard Performance Rating                            |   | Date of approval  |                                     |                        |                     |                        |                      |             |                    |
| Safeguard Performance Rating - Rationale                |   |   |                                     |                        |                     |                        |                      |             |                    |
| Financial Data  |   |   |                                     |                        |                     |                        |                      |             |                    |
|   | Total Cost and Source   |   |                                     |                        |                     | Available Funds (US\$) |                      |             |                    |
| Operations  | Original IDB  | Current IDB   | Local Counterpart                   | Co-Financing / Country | Total Original Cost | Current IDB            | Disb. Amount to Date | % Disbursed | Undisbursed Amount |
| EC-U0003  | 63,161,940  | 63,161,940  | 0                                   | 0                      | 63,161,940          | 63,161,940             | -                    | 0.00%       | 63,161,940         |
| Aggregated  | 63,161,940  | 63,161,940  | 0                                   | 0                      | 63,161,940          | 63,161,940             | -                    | 0.00%       | 63,161,940         |
| Expense Categories by Loan Contract (cumulative values) |   |   |                                     |                        |                     |                        |                      |             |                    |

Please note that inactive indicators and outputs are not displayed; totals in the actual cost table may not match the sum of the cost of the outputs displayed, due to the cost of inactive outputs.

RESULTS MATRIX

General Development Objectives

General Development Objectives Nbr. 1: Objetivo general de desarrollo: Contribuir a reducir la morbilidad y mortalidad por COVID-19

Observation:

| Indicator |   | Unit of Measure | Baseline | Baseline Year | Expected Year of Achievement | EOP 2037 |        |
|-----------|---|-----------------|----------|---------------|------------------------------|----------|--------|
| 1.0       | Número de muertes provocadas por COVID-19 | Número          | 55968    | 2023          | 2023                         | P        | 30,502 |
|           |   |                 |          |               |                              | A        | -      |
| Details   |   |                 |          |               |                              |          |        |

Means of Verification: Informe de la Coordinación de Planificación del MSP en base a datos hospitalarios y de vigilancia epidemiológica del MSP

Observations: Línea de base representa el escenario de “control” (número estimado de muertes acumuladas al nivel nacional (sistema público y privado), si el MSP no distribuiría vacunas contra COVID-19). La meta representa la estimación de muertes en caso de una campaña de inmunización masiva (con vacunas COVAX y otras bajo acuerdos bilaterales). Las estimaciones incluyen muertes poro conCOVID-19 de casos confirmados y probables. La dirección deseada del indicador es minimizar el valor EOP. Cálculo línea base: 13.992 (muertes 2020, estimación actualizada al 27 de diciembre2020) por cuatro años (2020-2023) = 55.968 Cálculo EOP: Evitar 73%\*de las muertes en 2022-2023 y 36% en 2021: (13.992 muertes por dos años (2022-2023) x0.27) + (13.992 muertes (2021) x 0.64) +13.992 (muertes 2020) = 30.502Seguimiento de los temas de género: Línea base 67%hombres y 33% mujeres

The General Development Objective indicator target is expected to be observed by the operation's "Fully Justified" date in Convergence (CO): Yes

| Pro-Gender | No                                      | Pro-Ethnicity | No | CRF indicator   |          |               |                              |          |         |
|------------|---|---------------|----|-----------------|----------|---------------|------------------------------|----------|---------|
|            |   |               |    |                 |          |               |                              |          |         |
| Indicator  |   |               |    | Unit of Measure | Baseline | Baseline Year | Expected Year of Achievement | EOP 2037 |         |
| 1.3        | Número de casos de COVID-19 confirmados |               |    | Número          | 837420   | 2023          | 2023                         | P        | 341,248 |
|            |   |               |    |                 |          |               |                              | A        | -       |
| Details    |   |               |    |                 |          |               |                              |          |         |

Means of Verification: Informe de la Coordinación de Planificación del MSP en base a datos de vigilancia epidemiológica del MSP

Observations: Línea de base representa el escenario de “control” (número estimado de casos acumulados al nivel nacional (sistema público y privado), si el MSP no distribuiría vacunas contra COVID-19). La meta representa la estimación de casos en caso de una campaña de inmunización masiva (con vacunas COVAX y otras bajo acuerdos bilaterales). Las estimaciones incluyen casos confirmados mediante prueba PCR. La dirección deseada del indicador es minimizar el valor EOP. Cálculo línea base: 209.355 (casos 2020, estimación actualizada al 27 de dic 2020) por cuatro años (2020-2023)= 837.420 Cálculo EOP: Evitar 47% de los casos en 2021 y 95% de los casos en2022-2023: (209.355 (casos 2021)x 0.53) +(209.355 casos por dos años (2022-2023) x 0.05) +209.355 (casos 2020) = 341.248 Seguimiento de los temas de género: Línea base 53% hombres y 47% mujeres

The General Development Objective indicator target is expected to be observed by the operation's "Fully Justified" date in Convergence (CO): Yes

|            |    |               |    |               |  |  |  |
|------------|----|---------------|----|---------------|--|--|--|
| Pro-Gender | No | Pro-Ethnicity | No | CRF indicator |  |  |  |
|            |    |               |    |               |  |  |  |

RESULTS MATRIX

Specific Development Objectives

Specific Development Objectives Nbr. 1: Apoyar esfuerzos para interrumpir la cadena de transmisión de la enfermedad

Observation:

| Indicator |   | Unit of Measure | Baseline | Baseline Year |   | 2021      | 2022 | 2023 | 2037 |
|-----------|---|-----------------|----------|---------------|---|-----------|------|------|------|
| 1.0       | Número de personas de los grupos priorizados vacunadas contra la COVID-19 | Número          | 0        | 2020          | P | 3,528,600 | -    | -    | -    |
|           |   |                 |          |               | A | -         | -    | -    | -    |

Details

Means of Verification: Sistema Nacional de Registro de la Inmunización contra COVID-19 del MSP

Observations: La estimación del indicador se refiere a la población de Ecuador mayor de 18 años, excluyendo mujeres embarazadas y en etapa de lactancia y menores de 18 años, con corte al 30 de dic 2020, según proyección poblacional base al censo 2010 del INEC. La meta supone una entrega del 50% delas vacunas de COVAX en 2021, 50% en 2022y un tipo de vacuna que prevé dosdosis por persona, sin considerar pérdidas de dosis.

Evaluation Methodology: -

|            |    |               |    |               |  |
|------------|----|---------------|----|---------------|--|
| Pro-Gender | No | Pro-Ethnicity | No | CRF indicator |  |
|            |    |               |    |               |  |

RESULTS MATRIX

OUTPUTS: ANNUAL PHYSICAL AND FINANCIAL PROGRESS

Component Nbr. 1 Componente 1. Interrupción de la cadena de transmisión

|      |  |                 |       | PHYSICAL PROGRESS |           | FINANCIAL PROGRESS |          |
|------|--|-----------------|-------|-------------------|-----------|--------------------|----------|
|      | Output   | Unit of Measure |       | 2021              | EOP 2037  | 2021               | EOP 2037 |
| 1.01 | 1.1. Número de dosis de vacunas contra COVID-19 entregadas | Número          | P     | 4,469,850         | 7,057,200 | -                  | -        |
|      |  |                 | P (a) | 4,469,850         | 7,057,200 | -                  | -        |
|      |  |                 | A     | 4,469,850         | 4,469,850 | -                  | -        |

| Total Cost |            |  |       |           |           |
|------------|------------|--|-------|-----------|-----------|
|            | Total Cost |  | P     | 4,469,850 | 7,057,200 |
|            |            |  | P (a) | 4,469,850 | 7,057,200 |
|            |            |  | A     | 4,469,850 | 4,469,850 |

| EOP 2037  |
|-----------|
| 3,528,600 |
| -         |

No information available for this section

RISKS AND PLANNED RESPONSES

| Risk ID | Risk Status      |                     | Risk Taxonomy |
|---------|------------------|---------------------|---------------|
| 1       | Active           |                     | Planning      |
|         |                  |                     |               |
|         | Response Actions |                     |               |
|         | 1.0              | Management Strategy | Status        |
|         |                  | -                   |               |
|         |                  |                     |               |
|         |                  |                     |               |

| Risk ID | Risk Status      |                     | Risk Taxonomy |
|---------|------------------|---------------------|---------------|
| 2       | Active           |                     | Planning      |
|         |                  |                     |               |
|         | Response Actions |                     |               |
|         | 2.0              | Management Strategy | Status        |
|         |                  | -                   |               |
|         |                  |                     |               |
|         |                  |                     |               |

| Risk ID | Risk Status      |                     | Risk Taxonomy         |
|---------|------------------|---------------------|-----------------------|
| 3       | Active           |                     | Political Environment |
|         |                  |                     |                       |
|         | Response Actions |                     |                       |
|         | 3.0              | Management Strategy | Status                |
|         |                  | -                   |                       |
|         |                  |                     |                       |
|         |                  |                     |                       |

IMPLEMENTATION STATUS AND LEARNING

| Lesson Learned - Categories |
|-----------------------------|
| Stakeholder Priorities      |